Skip to content Skip to footer
Week Ending Friday, November 20, 2026 U.S. stocks finished a turbulent week with a sharp Friday selloff as concerns about artificial intelligence valuations, infrastructure financing and policy uncertainty overwhelmed an improvement in consumer confidence. The Nasdaq Composite dropped 5.28% in the final…
SER-252 Advances as the Bullish Case Moves From Platform Promise to Clinical Execution For a small biotechnology company, progress is best measured in patients dosed, safety reviews completed and the quality of the next clinical question. By those measures, Serina Therapeutics (NYSE American:…
Serina's SER-252 Puts a Practical Innovation at the Center of the Story Biotechnology often commands attention by promising an entirely new molecule. Serina Therapeutics (NYSE American: SER) is pursuing a different proposition: take an established therapeutic agent, improve how it reaches the patient and…
Healthcare’s most compelling growth stories often begin with an unglamorous proposition: make an existing problem less difficult to manage. For INOVIO Pharmaceuticals (NASDAQ: INO), that means a newly approved immunotherapy intended to reduce repeated surgeries. For IDEXX Laboratories (NASDAQ: IDXX), it means…